This Dividend Stock's Secret Weapon?

By Max Macaluso and Dave Williamson – Sep 18, 2013 at 6:23PM

NYSE: ABBV

AbbVie

Market Cap

$297B

Today's Change

(-0.84%) -$1.42

Current Price

$166.38

Price as of April 25, 2024, 10:11 a.m. ET

Investors should take a closer look at AbbVie's drug development pipeline.

When investors discuss pharmaceutical company AbbVie (ABBV -0.84%), the conversation tends to steer toward its key product, Humira, which reigns as both the company's biggest cash generator and the best-selling medication in the world. But arguably the biggest opportunities that AbbVie has going forward are the experimental drugs in its pipeline. What does this growing pharma have in clinical trials today?

In the following video, from The Motley Fool's health-care show Market Checkup, analysts David Williamson and Max Macaluso shine the spotlight on AbbVie's pipeline and explain what investors need to watch.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D., owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences. We Fools don't all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.